Randomized Trialhigh evidence
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.
The lancet. Diabetes & endocrinology·November 1, 2025·PMID 40961952
Why it mattersFor patients with obesity who do not achieve sufficient weight loss on semaglutide 2.4 mg, the 7.2 mg dose offers a more effective option with a manageable safety profile, potentially expanding treatment goals.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled